In the Dog House: Hoffman-La Roche

Hoffmann-La Roche, maker of saquinavir (Invirase and Fortovase) and ddC (HIVID) for setting the price of their new drug for hepatitis C, called Pegasys, even higher than that charged by Schering Plough for a similar drug.

Schering's price, at around $14,000 per year, was already so high that most people considered it immoral, but despite the impending crisis in funding for drugs, Roche topped them, charging nearly $15,000. Pegasys must be used in combination with a second drug, ribavirin, so the true price is higher still.

Want to tell them how you feel about this? Write or email:
George Abercrombie
President & CEO
Hoffmann-La Roche
340 Kingsland St.
Building 85, 8th Floor
Nutley, NJ 07110
george.abercrombie@roche.com